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Background:MTDH is overexpressed in breast cancers and promotes resistance to multiple chemotherapeutic agents.We
hypothesized thatMTDHmay contribute to TRAIL resistance in breast cancer.
Results:MTDHmodulatedTRAIL resistance in breast cancer cells through caspase-8 down-regulation andBcl-2 up-regulation.
Conclusion: The findings uncovered novel mechanisms of TRAIL resistance mediated byMTDH.
Significance:MTDH can be considered as a novel target for overcoming TRAIL resistance in breast cancer.
Metadherin (MTDH), the newly discovered gene, is overex-
pressed inmore than 40% of breast cancers. Recent studies have
revealed thatMTDH favors an oncogenic course and chemore-
sistance. With a number of breast cancer cell lines and breast
tumor samples, we found that the relative expression of MTDH
correlated with tumor necrosis factor-related apoptosis-induc-
ing ligand (TRAIL) sensitivity in breast cancer. In this study, we
found that knockdown of endogenous MTDH cells sensitized
the MDA-MB-231 cells to TRAIL-induced apoptosis both in
vitro and in vivo. Conversely, stable overexpression ofMTDH in
MCF-7 cells enhanced cell survival with TRAIL treatment.
Mechanically, MTDH down-regulated caspase-8, decreased
caspase-8 recruitment into the TRAIL death-inducing signaling
complex, decreased caspase-3 and poly(ADP-ribose) polymer-
ase-2 processing, increased Bcl-2 expression, and stimulated
TRAIL-induced Akt phosphorylation, without altering death
receptor status. In MDA-MB-231 breast cancer cells, sensitiza-
tion to TRAIL upon MTDH down-regulation was inhibited by
the caspase inhibitor Z-VAD-fmk (benzyloxycarbonyl-VAD-
fluoromethyl ketone), suggesting that MTDH depletion stimu-
lates activation of caspases. In MCF-7 breast cancer cells,
resistance toTRAILuponMTDHoverexpressionwas abrogated
by depletion of Bcl-2, suggesting that MTDH-induced Bcl-2
expression contributes to TRAIL resistance. We further con-
firmed that MTDHmay control Bcl-2 expression partly by sup-
pressing miR-16. Collectively, our results point to a protective
function of MTDH against TRAIL-induced death, whereby it
inhibits the intrinsic apoptosis pathway through miR-16-medi-
ated Bcl-2 up-regulation and the extrinsic apoptosis pathway
through caspase-8 down-regulation.
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)3 is a member of the TNF super family that can initiate
apoptosis via activation of the extrinsic apoptosis pathway (1,
2). It has emerged as a potential therapeutic agent due to its
remarkable feature of selectively inducing apoptosis in cancer
cells while sparing normal cells (3). TRAIL can effectively
induce apoptosis in various types of cancer cells (4). Ongoing
and completed phase I and phase II clinical trials with TRAIL
are showing clinically promising outcomes with no apparent
toxicity (5, 6). However, recent studies have indicated that a
variety of cancer cells are resistant to the apoptotic effects of
TRAIL (7–9), and it is notable that themajority of breast cancer
cells are resistant to TRAIL-mediated apoptosis (10). The
mechanisms underlying resistance to TRAIL are not fully
understood, and the identification of TRAIL resistance factors
could facilitate the development of more effective TRAIL-
based cancer therapies.
A newly discovered gene,metadherin (MTDH, also known as
AEG-1 or Lyric, a membrane protein with a large C-terminal
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cytoplasmic domain), is frequently overexpressed in primary
tumor tissues, and its expression level is always associated with
the progression and/or worse prognosis of various types of can-
cers, such as breast cancer (11, 12), prostate cancer (13), neu-
roblastoma (14), and hepatocellular carcinoma (15). MTDH is
overexpressed in more than 40% of breast cancers and plays a
role in breast cancer progression and metastasis (16–18). As a
potent mediator in the development of malignancies, MTDH
participates inmultiple pathological steps, includingmalignant
transformation, angiogenesis, and metastasis (19). In addition,
a more general role for MTDH as a possible mediator of broad
spectrum chemoresistance has been indicated recently (19, 20).
NCI60 pharmacogenomic data revealed a significant correla-
tion between MTDH overexpression and resistance of cancer
cells to a broader spectrum of chemical compounds (19, 21).
Subsequent in vitro and in vivo chemoresistance analyses
showed that MTDH knockdown sensitizes several different
breast cancer cell lines to paclitaxel, doxorubicin, and cisplatin
(21, 22).
Considering the role of MTDH in drug resistance, we
hypothesized that MTDH may be a potential target to over-
comeTRAIL resistance of breast cancer cells. Here, we demon-
strate that MTDH contributes to TRAIL resistance in breast
cancer cells both in vitro and in vivo through Bcl-2 up-regula-
tion and/or caspase-8 down-regulation. Our findings suggest
thatMTDH inhibitionmay be used to restore TRAIL sensitivity
in TRAIL-resistant breast cancers.
EXPERIMENTAL PROCEDURES
Production of Recombinant Human TRAIL (rhTRAIL)—
rhTRAIL was produced essentially as described previously (23,
24). Briefly, M15 pRep4 bacteria with a modified inducible
pQE9 expression plasmid (Qiagen) coding for the sequence
MRGSHHHHHHGSEQKLISEEDLNLQ (His6-Myc) followed
by amino acids 95–281 of human TRAIL were used (25). Bac-
teria were grown to an optical density of 0.7 at 600 nm, induced
with 50 g/ml of isopropyl-1-thio--D-galactopyranoside for
18 h at 37 °C, harvested, and suspended in B-PER lysis buffer
(Thermo Fisher Scientific) according to the manufacturer’s
instructions. After centrifugation, the cleared supernatant was
filtered at 0.22 m and loaded onto a HiTrap chelating column
(GE Healthcare). Nonspecific proteins were removed by wash-
ing with 2 column volumes of TBS (10 mM Tris-HCl, pH 7.4,
140 mM NaCl) containing 10 mM imidazole followed by 2 col-
umn volumes of TBS, 50 mM imidazole. rhTRAIL was then
eluted with TBS, 0.5 M imidazole and dialyzed against TBS in a
dialysis bag with a 15-kDa molecular mass cutoff.
Patients and Samples—A consecutive series of surgically
resected primary invasive breast carcinomaswas retrieved from
the Qilu Hospital of Shandong University, Jinan, China. For all
participants in this study, written informed consent was
obtained as delineated by the protocol that was approved by the
Ethical Committee of Shandong University. None of the
patients received chemotherapy or irradiation therapy prior to
the surgery. Surgically resected breast cancer tissues were
quickly divided into two samples; one was for histoculture drug
response assay (HDRA) of TRAIL, and the other was stored at
80 °C for the following Western blotting analysis.
HDRA—HDRA was conducted according to the previous
study (26). Briefly, different concentrations of rhTRAIL were
dissolved in DMEM/high glucose medium (Life Technologies)
containing 20%FBS (Tian JinHaoYangBiologicalManufacture
Co., Ltd., Tianjin, China) and penicillin-streptomycin-ampho-
tericin B. Then 1 ml of solution/well was added into a 24-well
plate. The cut-off concentration used to distinguish in vitro
sensitivity and resistance was500 ng/ml for rhTRAIL. The
pieces of tumor tissues were placed on the gelatin foam of each
well and were incubated for 7 days. Then 100 l of 3-(4,5-dim-
ethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)
solutions, containing 50 mM sodium succinate, was added to
each well. After the plates were incubated for a further 16 h, the
medium was removed from each well, and 500 l of dimethyl
sulfoxide (DMSO) per well was added to extract MTT forma-
zan. After 2 h, 100 l of solution was extracted from each well
and transferred to 96-well multiplate. The relative survival was
calculated as T/C  100, where T is mean absorbency of the
treated wells per gram tumor, and C is mean absorbency of the
control wells per gram of tumor.
Cells and Culture Conditions—The breast cancer cell lines
MCF-7 and MDA-MB-231 were obtained from the American
Type Culture Collection (ATCC, Manassas, VA), and the cells
were routinely cultured in DMEM/high glucose medium sup-
plemented with 10% FBS, 100 units/ml penicillin, and 100
g/ml streptomycin. Jurkat cells were cultured in RPMI 1640
(Gibco) supplemented with 10% FBS and antibiotics. All the
cells were cultured at 37 °C, 5% CO2.
Plasmid, siRNA, and Transfection—The overexpression and
knockdown plasmids were constructed as described previously
(22). Briefly, the cDNA ofMTDH was cloned into the multiple
cloning site of the pcDNA3.1 vector (Invitrogen), and the plas-
midwas controlled by sequencing. The 19-nucleotide sequence
5-ATGAACCAGAATCAGTCAGC-3 was used to generate
MTDH shRNA. The 60-nucleotide oligonucleotides were
annealed and inserted into the pSUPER.retro.puro vector (Oli-
goEngine, Seattle, WA). Small interfering RNAs (siRNAs) uti-
lized for Bcl-2 and caspase-8 knockdown were purchased from
Cell Signaling Technology (Danvers, MA). Mimics and inhibi-
tor ofmir-16 and the corresponding negative control (Shanghai
GenePharma, Shanghai, China) were used to achieve overex-
pression or knockdown of miR-16 (sequence can be found in
supplemental Table S1). Cells were transfected with Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
protocol. When necessary, cells were selected with 0.3 mg/ml
G418 for pcDNA 3.1 based-vectors or 0.5g/ml puromycin for
pSUPER.retro.puro-based vectors. Transiently transfected
cells were harvested at 48 h for mRNA and at 72 h for protein
analysis.
Real-time PCR and Quantitative PCR Analysis—Total RNA
was extracted from cultured cells with TRIzol reagents (Invit-
rogen) according to the manufacturer’s protocol. The concen-
tration of total RNA was quantified by measuring the absorb-
ance at 260 nm. Total RNAwas reverse transcribed to cDNAby
using the PrimeScript RT reagent kit (Takara, Dalian, China).
The first-strand cDNA of miRNA was synthesized in two steps
using the miRcute miRNA first-strand cDNA synthesis kit
(Tiangen Biotech, Beijing, China). Real-time PCR was per-
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formed with the SYBR Green Premix Ex Taq II (Takara) with
the Applied Biosystems StepOne Plus real-time PCR system
(Applied Biosystems, Carlsbad, CA). The expression of glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) was used as
the endogenous control for detection of mRNA expression
level, whereas U6 was used as endogenous control for
microRNA expression analysis. Relative quantification analysis
was performed using the comparative CT (2CT) method.
Primer information used in the study can be found in supple-
mental Table S2.
Flow Cytometry Analysis—The phycoerythrin-conjugated
anti-DR4, anti-DR5, and control mouse IgG are from eBiosci-
ence (SanDiego, CA). Themembrane protein levels of DR4 and
DR5 were analyzed by flow cytometry as described previously
(27). Vehicle- or TRAIL-treated cells were incubated with the
phycoerythrin-conjugated anti-DR4 or anti-DR5 monoclonal
antibody (1:100 dilution) for 1 h at 4 °C. After three washes,
cells were analyzed immediately on a FACScan (BD
Biosciences).
Western Blot Analysis—Cells were collected and lysed with
radio immunoprecipitation assay buffer (PBS, 1% Nonidet
P-40, 0.1% SDS, 5 mM EDTA, 0.5% sodium deoxycholate, 1 mM
sodium orthovanadate) with protease inhibitors. Equal
amounts of proteins were resolved on SDS-PAGE gels and then
transferred to a PVDF membrane (Millipore, Bedford, MA).
After blocking with 5% nonfat milk, the membrane was incu-
bated overnight at 4 °C with the primary antibody (Immuno-
Way Biotechnology Co., Newark, DE) and then with horserad-
ish peroxidase-coupled secondary antibody. Signal was
detected with enhanced chemiluminescence (ECL).
Cell Viability Assay—Cell viability was assessed by the MTT
assay. MCF-7 cells and MDA-MB-231 cells were plated at a
density of 3 103 and 1 103 cells/well in 96-well plates. After
incubation at 37 °C, 20 l of MTT (5 mg/ml in PBS) was added
to each well, and cells were incubated for another 4 h at 37 °C.
The supernatants were carefully removed, and 100l of DMSO
was added to each well. The plates were gently shaken for 10
min, and the absorbance values were measured at 490 nm with
a microplate reader (Bio-Rad).
In Vivo Experiments—MDA-MB-231 vector and MDA-MB-
231 shMTDH cells (5 106 cells in 100l of PBS:Matrigel (1:1,
v/v)) were injected subcutaneously into each flank of 4–5-
week-old BALB/c nu/nu mice as described (22). Three weeks
later, mice were treated intraperitoneally four times per week
with rhTRAIL at 7.5 mg/kg or with the corresponding drug
vehicle (TBS) (28, 29). Tumor growth wasmonitored weekly by
size measurement. Both maximum (L) and minimum (W)
length of the tumor were measured using a slide caliper, and
the tumor volume was calculated as 1⁄2 LW2.Whenmice were
sacrificed, tumors were dissected and embedded in paraffin,
and 4-m slides were subjected to terminal nucleotidyl
transferase-mediated nick end labeling assay (Beyotime
Institute of Biotechnology, Beijing, China). These experi-
ments were approved by the Animal Care and Use Commit-
tee of Shandong University.
Immunoprecipitation of the Death-inducing Signaling Com-
plex (DISC)—Biochemical analysis of the DISC was performed
as described previously (30, 31). The stimulation mix contain-
ing 1 g/ml His6-TRAIL and 2 g/ml anti-His6 mouse mono-
clonal antibody (Cell Signaling Technology) was incubated for
30min at 37 °C before use. Then 1 107MDA-MB-231 cells or
MCF-7 cells were washed with prewarmed DMEM and treated
with the stimulation mix for 30 min at 37 °C. The stimulation
was terminated by adding 25 ml of ice-cold PBS. Cells were
harvested at 4 °C and lysed with 1 ml of lysis buffer. For the
unstimulated control, the cells were lysed before the addition of
the stimulation mix. His6-TRAIL-induced DISC was immuno-
precipitated with protein A/G Plus-agarose beads (Santa Cruz
Biotechnology, Santa Cruz, CA) and subjected toWestern blot
analysis.
MicroRNA Array Analysis—Total RNA isolation was per-
formed with TRIzol reagents (Invitrogen) according to manu-
facturer’s protocol. The concentration of total RNA was quan-
tified by measuring the absorbance at 260 nm.
A microarray containing 873 miRNA probes was made
(designed according to miRBase release 12.0). miRNA probe
design, RNA labeling, and microarray hybridization were per-
formed as described elsewhere (32, 33). Briefly, total RNA (2.5
g) was labeled with pCp-DY647 (Dharmacon, Lafayette, CO).
After hybridization, we scanned arrays with the LuxScan 10K
microarray scanner (CapitalBio, Beijing, China), and analyzed
images with GenePix Pro 6.0 software (Axon Instruments, Fos-
ter City, CA). For data processing, we first performed back-
ground subtraction and quantile normalization and then
excludedmiRNAs from the analysis when theywere not detect-
able in both samples. We used Biometric Research Branch-Ar-
rayTools version 3.8.0 (linus.nci.nih.gov/BRB-ArrayTool-
s.html) for microarray data analysis.
Statistical Analysis—The software SPSS version 18.0 was
used for statistical analysis. Student’s t test and one-way analy-
sis of variance analysis were used to determine significance.
IC50 was calculated with probit regression analysis. All error
bars represent the S.E. of three experiments. Differences with
p 0.05 were considered significant.
RESULTS
Generation of Recombinant Human TRAIL—A soluble form
of His-tagged rhTRAIL was isolated by chelation affinity puri-
fication, and protein purity was confirmed by SDS-PAGE and
Coomassie Blue staining (supplemental Fig. S1). The protein
killed TRAIL-sensitive Jurkat cells with potency comparable
with that of a commercial product (data not shown).
HighExpression ofMTDHWasCorrelatedwithTRAILResist-
ance in Breast Cancer Cells and Breast Tumor Samples—
To explore whether relative expression of MTDH correlates
with TRAIL resistance in breast cancer, we detected TRAIL
sensitivity and MTDH expression in a variety of breast cancer
cell lines and the nontransforming MCF-10A breast cells. A
previous study indicated that TRAIL selectively induced apo-
ptosis in cancer cells while sparing normal cells (3), which may
explain why MCF-10A is most resistant to TRAIL although it
has the lowest level of MTDH. HS578T andMCF-7 breast can-
cer cells showed relatively high expression levels ofMTDH and
were more resistant to TRAIL treatment. Nevertheless, the
other cell lines expressing relatively low levels of MTDH were
more sensitive to TRAIL (Fig. 1, A and B). We chose the most
MTDHModulates TRAIL Resistance in Breast Cancer
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resistantMCF-7 cell line and the most sensitiveMDA-MB-231
cell line in the following study.
To further evaluate the contribution of MTDH to TRAIL
resistance, we conductedHDRA.We collected 16 breast tumor
tissues and the paired normal tissues for HDRA from patients
diagnosedwith invasive ductal carcinoma. As is shown in Fig. 1,
C and D, the susceptibility of MTDH-negative tumors to
TRAIL was significantly higher than that of MTDH-positive
tumors (p 0.0225). TheHDRA results suggested a correlation
between MTDH expression and TRAIL resistance in breast
carcinomas.
MTDH Modulated TRAIL Resistance Both in Vitro and in
Vivo—To determine whetherMTDHmodulates TRAIL resist-
ance in breast cancer cells, we generated stable MCF-7 cells
overexpressing MTDH and stable MDA-MB-231 cells with
shRNA-mediated knockdown of MTDH. Efficient overexpres-
sion of MTDH in MCF-7 cells and knockdown of MTDH in
MDA-MB-231 was validated by real-time PCR and Western
blotting (Fig. 2, A and B).
To investigate the role ofMTDH in TRAIL-induced apopto-
sis, we tested whether exogenous expression or knockdown of
MTDH could regulate TRAIL resistance in breast cancer cell
lines. MCF-7 cells overexpressing MTDH showed enhanced
resistance to TRAIL at various concentrations of rhTRAIL (Fig.
2C). Consistently, we found that resistance to rhTRAIL was
significantly attenuated by knockdownofMTDH inMDA-MB-
231 cells (Fig. 2D), indicating that MTDH expression may pro-
mote resistance to rhTRAIL. We also calculated the potencies
to directly compare the sensitivity to TRAIL of each cell lines
(Table 1).
Next, we studied the effect ofMTDH on TRAIL sensitivity in
vivo using a xenograft model. MDA-MB-231 cells knocked
down or not forMTDHwere injected subcutaneously into each
flank of nude mice. Administration of TRAIL (7.5 mg/kg, four
times per week) or the drug vehicle was initiated 3 weeks later.
As shown in Fig. 3,A and B, MDA-MB-231 cells knocked down
for MTDH grew slower than wild type controls in the absence
of treatment. Administration of TRAIL further significantly
suppressed tumor growth in MDA-MB-231 shMTDH but had
no visible effect on control cells. Apoptosis induced by TRAIL
in tumor tissues was measured by a terminal nucleotidyl trans-
ferase-mediated nick end labeling (TUNEL) assay. TUNEL-
positive cells were detected at higher frequency in tumors
derived from MDA-MB-231 shMTDH cells than in those
FIGURE1.ExpressionofMTDHcorrelateswithTRAIL resistance inbreast cancer cell linesandbreast tumorsamples.A, relative survival of eachbreast cell
line was tested with MTT assay after a 48-h treatment with rhTRAIL. Points are the average of three independent experiments; error bars represent S.E.
B, expression level of MTDH was compared with Western blotting among these cell lines. -Actin was used as the endogenous control. C, the sensitivity to
rhTRAIL studied in the MTDH-negative () group was significantly higher than that in the positive () group (p  0.0225). D, the expression of MTDH was
determined with Western blotting, and -actin was used as the loading control. N, paired normal tissue; T, tumor tissues.
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derived from control cells (Fig. 3, C and D), in good agreement
with the observation that TRAIL selectively impaired growth of
tumors knocked down for MTDH. These data indicated that
MTDH suppression may function as an effective sensitizer to
TRAIL-based therapy in breast cancer.
MTDHDid Not Regulate Death Receptor (DR) or c-FLIP Pro-
tein Levels but Increased Bcl-2 and Decreased Caspase-8 Ex-
pression Levels—As both in vitro and in vivo analyses pointed to
a role of MTDH in the resistance of breast cancer cell lines to
TRAIL, we examined expression levels of proteins known to
either favor or counteract TRAIL-induced cell death (5).
TRAIL binds to two death domain-containing receptors
(TRAILR1/DR4 and TRAILR2/DR5) that can trigger cell death
and two decoy receptors (TRAILR3/DcR1 and TRAILR4/
DcR2) proposed to be protective. The expression of DcR1 and
DcR2 at themRNA level, detected by real-time PCR, showed no
correlation with MTDH expression (data not shown). Surface
DR4 and DR5 expression was assessed by flow cytometry, and
FIGURE 2. Stable overexpression and knockdown of MTDH in breast cancer cell lines and MTDH contributes to TRAIL resistance in vitro. A, stable
MDA-MB-231 cells expressing an MTDH-targeting shRNA (shMTDH) or the control pSUPER.retro.puro empty vector (Vector) (left) and stable MCF-7 cells
transfectedwith anMTDHexpression plasmid (MTDH) or the control pcDNA3.1 empty vector (Vector) (right) were analyzed forMTDHmRNA levels by real-time
PCR after 2weeksof selection. Columns represent averageof three independentexperiments; error bars represent S.E.; *,p0.05; **,p0.01 versus cells transfected
with control vector. B, the transfection efficiencywas confirmedbyWestern blot analysis. Cell extractswere prepared forWestern blotting ofMTDH, and-actinwas
usedas theendogenouscontrol. The figureshown is representativeof three independentexperiments.C,MCF-7vectorcells andMCF-7MTDHcellswere treatedwith
TRAIL for the indicated timepoints. The effect ofMTDHon TRAIL-induced apoptosiswasmeasured at different doses of TRAIL by theMTT assay andwas plotted as a
percentageof change relative to thecontrol.D, sensitizationof theMDA-MB-231cell linebyMTDHknockdown(shMTDH)wasmeasuredatdifferentdosesofTRAILby
theMTT assay. Points are the average of three independent experiments; error bars represent S.E.; *, p 0.05; **, p 0.01.
TABLE 1
Effect of rhTRAIL on cell viability assessed by the MTTmethod (ng/ml)
The effect of rhTRAIL on cell viability by the MTT assay is represented. The IC50 S.D. values were calculated based on the results of three independent experiments.
24 h 48 h 72 h
MCF-7 vector 8.586 0.934 1.041 0.017 0.602 0.221
MCF-7 MTDH 43.045 1.634 3.524 0.547 1.992 0.299
MDA-MB-231 vector 17.374 1.240 11.126 1.046 22.292 1.384
MDA-MB-231 shMTDH 9.036 0.956 4.712 0.673 5.605 0.749
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the results showed that DR4 and DR5 remained unchanged
(Fig. 4). ByWestern blot, DR4 and DR5 levels were not affected
by MTDH knockdown in MDA-MB-231 cells or by MTDH
overexpression in MCF-7 cells (Fig. 5A), suggesting that
MTDH has no major impact on TRAIL receptor expression.
FLIPS, a cellular inhibitor of caspase-8 activation, was detected
in MDA-MB-231 cells but was not regulated by MTDH levels.
In contrast, expression levels of caspase-8, the initiator caspase
immediately downstream of death receptors, negatively corre-
lated with those of MTDH. Conversely, levels of the antiapop-
totic protein Bcl-2, but not those of the proapoptotic protein
Bax, correlated with those of MTDH. In addition, and in line
with the observation that MTDH expression reduces cell sen-
sitivity to TRAIL, we detected enhanced processing of several
downstream executors of TRAIL-induced death inMTDH low
cells. MTDH depletion sensitized MDA-MB-231 cells to
TRAIL-induced processing of caspase-3 and poly(ADP-ribose)
polymerase-2 (Fig. 5B). Similarly, MTDH overexpression in
MCF-7 cells attenuated caspase-8 and poly(ADP-ribose)
polymerase-2 processing and activated more phospho-Akt in
response to TRAIL treatment (Fig. 5C).
Inhibition of TRAIL-induced Apoptosis Depended on the
Down-regulation of Caspase-8 and Decreased Recruitment of
Caspase-8 into the DISC—To study the implication of caspases
in TRAIL-induced death, cells with varying levels of MTDH
were treated with TRAIL in the presence of the pan-caspase
inhibitor Z-VAD-fmk. Z-VAD-fmk partially prevented death
induced by TRAIL inMCF-7 and inMDA-MB-231 cells (Fig. 6,
A and B). Notably, the decreased viability due toMTDH deple-
tion in MDA-MB-231 cells was entirely prevented by adding
Z-VAD-fmk before TRAIL treatment, suggesting that MTDH
prevents a caspase-dependent process in these cells (Fig. 6A).
However, the protective effect of MTDH overexpression in
MCF-7 cells was additive with that of Z-VAD-fmk, indicating
that factors other than caspasesmight be inhibited byMTDH in
MCF-7 cells (Fig. 6B).
We observed that caspase-8 was negatively regulated by
MTDH in breast cancer cells. We therefore knocked down
caspase-8 in both MBA-MB-231 vector and MTDH-targeting
shRNA (shMTDH) cells. As observed for Z-VAD-fmk, an effi-
cient knockdown of caspase-8 protected TRAIL-exposed
MDA-MB-231 cells against the increase in apoptosis observed
after MTDH depletion (Fig. 6C).
Finally, we tested the recruitment of caspase-8 in TRAIL-
induced DISC. His6-TRAIL-induced DISC was immunopre-
cipitated from MTDH-proficient or -deficient MCF-7 and
MDA-MB-231 cells. There was more caspase-8 in the DISC of
cells expressing little MTDH than in their respective controls
expressing more MTDH (Fig. 6D). This recruitment was spe-
cific as no caspase-8 was recruited when MDA-MB-231 or
MCF-7 cells were lysed prior to the addition of His6-TRAIL,
although His6-TRAIL was still able to co-immunoprecipitate
DR4 and DR5 under these conditions. We also observed
increased recruitment of DR5 into the DISC of MDA-MB-231
shMTDHcells when comparedwith vector control cells, but no
noticeable changes for other receptors in MDA-MD-231 and
MCF-7 cells (Fig. 6D). Taken together, these results indicate
that the depletion of MTDH leads to higher caspase-8 expres-
sion and recruitment into the DISC, which could explain the
observed sensitization of the cells to TRAIL.
FIGURE 3.MTDH contributes to TRAIL resistance in vivo. A, MDA-MB-231 vector and MDA-MB-231 shMTDH cells were injected subcutaneously into each
flank of BALB/c nu/nu mice. Three weeks later, mice were treated intraperitoneally with the drug vehicle or with rhTRAIL at 7.5 mg/kg, four times per week.
Tumor volumewasmeasuredweekly bydirect caliper. Error bars represent S.E.; *,p0.05 versus control vehicle-treatedmice.B, representative tumors isolated
frommice 5weeks after implantationwith control (Vector) orMTDH-depleted (shMTDH) MDA-MB-231 cells and treatedwith rhTRAIL or vehicle as described in
panel A. C, representative TUNEL staining (red fluorescence) of MDA-MB-231 breast cancer xenografts shown in panel B. D, quantification of terminal deoxy-
nucleotidyl transferase-mediated dUTP nick end labeling-positive cells. Columns represent average of three independent experiments; error bars represent
S.E.; *, p 0.05; **, p 0.01, significantly different from respective control.
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MTDH Up-regulated Bcl-2 Protein Levels through Suppres-
sion of MicroRNA-16—MTDH and Z-VAD-fmk protected
MCF-7 cells from TRAIL by mechanisms that were at least
partially different (Fig. 6B), suggesting that factors distinct from
caspases regulate TRAIL resistance in these cells. The antiapo-
ptotic protein Bcl-2 regulates both caspase-dependent and
caspase-independent events leading to cell death (34). As Bcl-2
expression levels positively correlated with those ofMTDH, we
addressed the role of Bcl-2 in the regulation of TRAIL-induced
cell death in MCF-7 cells.
The benefit of MTDH expression in MCF-7 cells was lost
after knockdown of Bcl-2 in these cells, in accord with the
hypothesis that the Z-VAD-fmk-independent protective effect
of MTDH in MCF-7 cells is mediated by Bcl-2 (Fig. 7A). We
FIGURE 4. Flow cytometry analysis of surface protein levels of DR4 and DR5 after MTDH overexpression and knockdown. MTDH overexpression or
knockdown did not alter surface DR4 (top panel) and DR5 (bottom panel) protein levels in the presence or absence of TRAIL or vehicle, as determined by flow
cytometry. IgG was used as the negative control.
FIGURE 5. MTDH does not regulate DR or c-FLIP protein levels but increases Bcl-2 and decreases caspase-8 expression levels. A, expression of the
indicated proteins was examined in MTDH knockdown (shMTDH) or overexpressing (MTDH) cells, and in their respective controls (Vector), by Western blot
analysis. The blot for -actin was performed to confirm equal loading of samples. casp-8, caspase-8. B, MDA-MB-231 vector and shMTDH cells were treated for
12 hwith () orwithout () TRAIL at 40 ng/ml and then analyzedbyWesternblotting for the indicatedproteins.C, MCF-7 cells stably expressingMTDH (MTDH)
and their control (Vector) were treated for 24 h with () or without () TRAIL at 100 ng/ml and analyzed byWestern blotting for the indicated proteins. p-Akt:
phospho-Akt.
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next wondered whetherMTDHmay promote Bcl-2 expression
by regulating levels of miRs. For this purpose, we applied miR
arrays to detect altered miRs due to MTDH overexpression or
knockdown (supplemental Fig. S2). The candidate microRNAs
targeting Bcl-2were identified based on threemicroRNA target
prediction tools: TargetScanHuman 5.1, PicTar, and miRBase.
In our study, microRNAs that were predicted by at least two of
the methods were defined as promising candidates that target
Bcl-2. The reverse target prediction analysis indicated that
there are potentially six microRNAs that target Bcl-2. The
expression levels of six candidate miRs were determined by
microRNA array (supplemental Table S3), and the quantitative
PCRmethod was adopted to confirm the changes in cells over-
expressing MTDH or knocked down for MTDH (Fig. 7B). The
consistency of the two methods was best observed for miR-16,
whose levels inversely correlated with those of MTDH. In
accordance with miR array data, miR-16 showed a decreased
expression to 0.65-fold in MCF-7 cells overexpressing MTDH
(Fig. 7B). In contrast, MTDH knockdown in MDA-MB-231
cells increased miR-16 expression to 1.51-fold. Based on these
results and miR-16 target prediction (Fig. 7, C–E), we hypoth-
esized thatMTDH could down-regulate the expression ofmiR-
16, thus increasing Bcl-2 expression in breast cancer cells.
To determine whether miR-16 could regulate Bcl-2 expres-
sion, we used miR-16 mimics or inhibitors to overexpress or
knock down miR-16, respectively (Fig. 7F). Overexpression of
miR-16 impaired expression of Bcl-2 in MCF-7 MTDH cells at
the protein level (Fig. 7G, left). In contrast, suppression of
miR-16 in MDA-MB-231 cells increased Bcl-2 expression in
both control and shMTDH cells (Fig. 7G, right). To draw a
closer association with miR-16 and consequent Bcl-2 expres-
sion, we tested the TRAIL resistance of MCF-7 cells after
miR-16 manipulation. After transfection with miR-16 mimics,
TRAIL resistance of MCF-7 MTDH cells was not higher than
that of MCF-7 vector cells, indicating that regulation of Bcl-2
via miR-16 contributes to the TRAIL-resistant role of MTDH
(Fig. 7H). Taken together, our data suggest that MTDH may
facilitate TRAIL resistance by suppressing miR-16 and there-
fore up-regulating Bcl-2 protein expression (Fig. 7I).
DISCUSSION
Recently, we identifiedMTDH as a novel oncogene through a
bioinformatic strategy (22). Further functional analyses re-
vealed thatMTDH increased chemoresistance in cancer cells.
According to our previous studies, MTDH does not alter
drug accumulation in cells but instead helps cells to survive
FIGURE 6. Inhibition of TRAIL-induced apoptosis depends on the down-regulation of caspase-8 and on decreased recruitment of caspase-8 into the
DISC. A, MDA-MB-231 vector cells andMDA-MB-231 shMTDH cells were treated with 100M Z-VAD-fmk (ZVAD). One hour later, cells were treated with () or
without () TRAIL at 20 ng/ml for an additional 24 h. Cell viability was quantified with the MTT assay. B, MCF-7 vector and MCF-7 MTDH cells were pretreated
for 1 hwith vehicle or 100MZ-VAD-fmkM and then exposed to vehicle or TRAIL at 80 ng/ml for an additional 24 h. Cell viability wasmonitoredwith theMTT
assay.C, MDA-MB-231 vector cells andMDA-MB-231 shMTDH cells were transfectedwith control (MOCK) or caspase-8 siRNA (si-Casp-8). After 2 days, cells were
treated for 24 hwith vehicle or TRAIL at 20 ng/ml. The efficiency of caspase-8 (Casp-8) knockdownwas assessed byWestern blotting using-actin as a loading
control. Cell viability was quantified with theMTT assay.D, MDA-MB-231 vector or shMTDH cells (left panel) andMCF-7 vector or MTDH cells (right panel) were
stimulated with His6-tagged TRAIL for 30 min. Cells were lysed, His6-TRAIL was immunoprecipitated (IP) with anti-His mouse mAb, and the co-immunopre-
cipitated DR4, DR5, or caspase-8 was detected by Western blotting. The negative control () was processed identically, except that TRAIL was added to cells
after lysis. -Actin was probed in cell lysates to ensure that similar amounts of lysate were used in the immunoprecipitation. A–C, columns represent average
of three independent experiments; error bars represent S.E.; *, p 0.05,**, p 0.01 when compared with controls.
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antineoplastic stresses, for example by suppressing the pro-
apoptotic protein BNIP3 (22). In addition, MTDH exerts
resistance to doxorubicin through up-regulation of multi-
drug resistance gene 1 (MDR1) protein at both translational
and post-translational levels. In the present study, we ex-
plored whether MTDH could modulate TRAIL resistance
and therefore act as a crucial mediator in the extrinsic apo-
ptosis pathway in breast cancer cells. This work provided
evidence that MTDH contributes to TRAIL resistance in
breast cancer cells.
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It has been widely recognized that resistance can occur at
different levels in the TRAIL death signaling pathway, from
receptors to downstream caspases and Bcl-2 family members
(35). Various molecular mechanisms can account for TRAIL
resistance, including differential expression of death receptors,
enhanced DISC recruitment, overexpression of c-FLIP, high
levels of Akt and NF-B activity, and defects in the release of
mitochondrial proteins (36, 37).Most human breast cancer cell
lines are highly resistant to TRAIL-induced apoptosis despite
the expression of the death receptors DR4 and/or DR5 (38),
indicating that TRAIL resistance in breast cancer cells is likely
mediated by defects downstreamof death receptor activation in
the TRAIL signaling pathway (29). In agreement with this, our
result showed thatMTDHhardly altered the expression of DR4
(when it was expressed at all) and DR5 in MDA-MB-231 and
MCF-7 cells. MTDH apparently had little impact on c-FLIP
expression. c-FLIPL and c-FLIPS, which are potent inhibitors of
DR4- and DR5-mediated apoptosis, were mostly undetectable
in the cell lines analyzed. Only FLIPS was detected in MDA-
MB-231 cells, but its levels were not regulated by MTDH.
Our observation that TRAIL-induced Akt phosphorylation
in MCF-7 cells was increased in cells overexpressing MTDH is
consistent with a previous study indicating that MTDH acti-
vates cell survival through a PI3K-Akt signaling pathway (39).
Activation of the PI3K-Akt axis may thus be one of the under-
lying mechanisms for MTDH-induced TRAIL resistance (40).
Importantly, our data also revealed that MTDH enhanced
TRAIL resistance of breast cancer cells through both down-
regulation of caspase-8 and reduced recruitment of caspase-8
in the DISC. How MTDH decreases caspase-8 expression is
presently unclear and requires further investigation. Whether
reduced recruitment of caspase-8 in theDISC simply reflects its
lower expression levels inMTDH-expressing cells orwhether it
is the result of a more complex mechanism also remains to be
studied. Along these lines, we observed in MDA-MB-231 cells
that althoughDR5 expression in total extracts was independent
on MTDH expression levels, DR5 was enriched in the DISC of
TRAIL in MTDH knockdown cells. It would be of interest to
investigate whether MTDH favors intracellular retention of
DR5 at the expense of the surface-expressed receptor. In any
case, enhanced caspase-8 recruitment to the DISC correlated
with increased sensitivity of the cells to TRAIL.
Furthermore, the antiapoptotic protein Bcl-2 has been
shown previously to protect breast carcinoma cell lines from
TRAIL-induced cytotoxicity (41). Interestingly, we found that
Bcl-2was up-regulated by overexpression ofMTDHand down-
regulated when MTDH was silenced. Moreover, endogenous
Bcl-2 in MCF-7 cells accounted for most of the resistance to
TRAIL provided by MTDH overexpression. MicroRNAs have
emerged as endogenous regulatory RNAs that pair to the
mRNAs of target genes to direct their post-transcriptional
repression (42). We identified miR-16 as a potential link
between the expression levels of MTDH and Bcl-2. Further
investigation and validation will be required to determine the
role played by other microRNAs identified in our study in their
ability to regulate Bcl-2 expression and resistance to cell death.
Interestingly, our results indicate that the protection provided
by MTDH and Bcl-2-in MCF-7 cells was not mimicked by a
pan-caspase inhibitor, suggesting that MTDH acts on a
caspase-independent pathway in these cells. This is somewhat
surprising as Bcl-2 is usually considered to act upstream of
cytochrome c release from the mitochondria, activation of the
caspase 9-containing apoptosome, and activation of down-
streamcaspases such as caspase-3 and -7.MCF-7 cells are, how-
ever, known as caspase-3-deficient (43), which would be in line
with a cell death that is less dependent on caspase activation.
Bcl-2 also prevents the release of cytotoxic mitochondrial pro-
teins that function independently of caspases, and it is not
excluded that it may also regulate the caspase-independent
RIP3-dependent necroptosis pathway (34). Thus, MTDH-me-
diated induction of Bcl-2 in MCF-7 cells may account for
increased resistance against caspase-independent death path-
ways induced by TRAIL.
It has been reported that overexpression of Bcl-2 conferred
protection against TRAIL in breast carcinomas (41), and
caspase-8 overexpression could facilitate TRAIL resistance
among cancer cells (44). Our results showed that shMTDH
could cause the up-regulation of caspase-8 and down-regula-
tion of Bcl-2 in the breast cancer cells. According to these
results, it can be inferred that the observed tumor suppression
effect by shMTDH in the xenograft model was associated with
altered level of Bcl-2 and/or caspase 8 of the tumor cells. Our
results, however, indicate that MTDH can also provide protec-
tion against the caspase-dependent arm of TRAIL-induced
death as depletion of MTDH increased the susceptibility of
MDA-MB-231 cells in a Z-VAD-fmk- and caspase-8
siRNA-inhibitable manner.
Taken together, our study shows that MTDH can increase
resistance of breast cancer cell lines to TRAIL. Although the
protection is partial,MTDH-induced protection is consistently
FIGURE 7.MTDHup-regulates Bcl-2 by reducing expressionofmicroRNA-16.A, MCF-7 vector orMTDH cells were transfectedwith either control (MOCK) or
Bcl-2 siRNAs (si-Bcl-2). After 2 days, cells were treated with vehicle or TRAIL at 20 ng/ml, as indicated. The transient knockdown of caspase-8 was validated by
Western blotting, using -actin as loading control. B, the abundance of miR-148a, miR-15a, miR-16, miR-21, miR-365b, andmiR-7 was monitored by real-time
PCR in MCF-7 vector and MTDH cells and MDA-MB-231 vector and shMTDH cells. Fold change represents the relative quantification of each microRNA versus
control cells. C, the alignment of themiR-16 targeting sequences located in the 3-untranslated region of the Bcl-2 genes from six organisms (Hsa, human; Ptr,
chimpanzee; Mml, mouse; Rno, rat; Cfa, dog; Gga, chicken). The evolutionarily conserved nucleotides are highlighted in light gray. D, the predicted miR-16
targeting sequence located in the 3-untranslated region (3-UTR) of Bcl-2 mRNA. The seed region is highlighted in light gray. E, structure of predicted duplex.
Minimum free energy (mfe) is24.1 kcal/mol. F, MCF-7 vector andMTDHcellswere transfectedwith 50nMmiR-16mimics () orwith a control oligonucleotide
(). MDA-MB-231 vector and shMTDH cells were transiently transfected with 50 nM miR-16 inhibitor () or with a control oligonucleotide (). miR-16
expression levels monitored by real-time PCR were normalized either to expression levels in MCF-7 vector cells or to those in MDA-MB-231 vector cells. G, the
MCF-7 and MDA-MB-231 cell lines were treated as described in panel F. Cell lysates were analyzed by Western blotting to detect the effect of miR-16 on the
expression of Bcl-2.NC: negative control.H, MCF-7 vector orMTDH cells were transfectedwith eithermiR-16mimic control ormiR-16mimics. After 2 days, cells
were treated with vehicle or TRAIL at 40 ng/ml. I, a schematic model of the mechanisms through which MTDHmodulates TRAIL-induced apoptosis in breast
cancer cells. FADD, Fas-Associated protein with death domain; Casp-8, caspase-8; PARP, poly(ADP-ribose) polymerase-2. In A, B, F, and H, columns represent
average of three independent experiments; error bars represent S.E.; *, p 0.05.
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observed in different cell lines with reproducible effects.
Enhanced resistance to TRAIL-induced death by MTDH may
involve different, partially overlapping mechanisms: Akt acti-
vation, up-regulation of Bcl-2 mediated by miR-16, down-reg-
ulation of caspase-8, and decreased recruitment of caspase-8
into the DISC. In addition, using a xenograft animal model, we
provide a proof of concept for the combination of TRAIL and
MTDH inhibition that may represent a promising targeted
therapy for breast cancer in the clinic and is definitely worth
further exploration.
Acknowledgments—We thank members of the Women’s Oncology
Laboratory (Shandong University) for valuable input and support
throughout this study, Xiulian Sun, Chao Liu, and YuWang for help-
ing to generate the rhTRAIL, and Meiyin Zhang for microRNA array
data analysis.
REFERENCES
1. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl,
J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995)
Identification and characterization of a new member of the TNF family
that induces apoptosis. Immunity 3, 673–682
2. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and
Ashkenazi, A. (1996) Induction of apoptosis by Apo-2 ligand, a newmem-
ber of the tumor necrosis factor cytokine family. J. Biol. Chem. 271,
12687–12690
3. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters,
S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L.,
Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh,
Z., and Schwall, R. H. (1999) Safety and antitumor activity of recombinant
soluble Apo2 ligand. J. Clin. Invest. 104, 155–162
4. Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M.,
Chin,W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin,
R. G., Rauch, C. T., Schuh, J. C., and Lynch, D. H. (1999) Tumoricidal
activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Nat. Med. 5, 157–163
5. Newsom-Davis, T., Prieske, S., andWalczak, H. (2009) Is TRAIL the holy
grail of cancer therapy? Apoptosis 14, 607–623
6. Mahalingam, D., Szegezdi, E., Keane,M., de Jong, S., and Samali, A. (2009)
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Cancer Treat. Rev. 35, 280–288
7. Zhang, L., and Fang, B. (2005) Mechanisms of resistance to TRAIL-in-
duced apoptosis in cancer. Cancer Gene Ther. 12, 228–237
8. Pallares, J., Llobet, D., Santacana, M., Eritja, N., Velasco, A., Cuevas, D.,
Lopez, S., Palomar-Asenjo, V., Yeramian, A., Dolcet, X., andMatias-Guiu,
X. (2009) CK2 is expressed in endometrial carcinoma and has a role in
apoptosis resistance and cell proliferation. Am. J. Pathol. 174, 287–296
9. Kim, E. H., Kim, S. U., Shin, D. Y., and Choi, K. S. (2004) Roscovitine
sensitizes glioma cells toTRAIL-mediated apoptosis by downregulation of
survivin and XIAP. Oncogene 23, 446–456
10. Rahman, M., Davis, S. R., Pumphrey, J. G., Bao, J., Nau, M. M., Meltzer,
P. S., and Lipkowitz, S. (2009) TRAIL induces apoptosis in triple-negative
breast cancer cells with a mesenchymal phenotype. Breast Cancer Res.
Treat. 113, 217–230
11. Li, J., Zhang, N., Song, L. B., Liao, W. T., Jiang, L. L., Gong, L. Y., Wu, J.,
Yuan, J., Zhang, H. Z., Zeng, M. S., and Li, M. (2008) Astrocyte elevated
gene-1 is a novel prognostic marker for breast cancer progression and
overall patient survival. Clin. Cancer Res. 14, 3319–3326
12. Li, C., Li, R., Song, H., Wang, D., Feng, T., Yu, X., Zhao, Y., Liu, J., Yu, X.,
Wang, Y., and Geng, J. (2011) Significance of AEG-1 expression in corre-
lation with VEGF, microvessel density, and clinicopathological character-
istics in triple-negative breast cancer. J. Surg. Oncol. 103, 184–192
13. Kikuno, N., Shiina, H., Urakami, S., Kawamoto, K., Hirata, H., Tanaka, Y.,
Place, R. F., Pookot, D., Majid, S., Igawa, M., and Dahiya, R. (2007) Knock-
down of astrocyte-elevated gene-1 inhibits prostate cancer progression
through upregulation of FOXO3a activity. Oncogene 26, 7647–7655
14. Lee, S. G., Jeon, H. Y., Su, Z. Z., Richards, J. E., Vozhilla, N., Sarkar, D., Van
Maerken, T., and Fisher, P. B. (2009) Astrocyte elevated gene-1 contrib-
utes to the pathogenesis of neuroblastoma. Oncogene 28, 2476–2484
15. Yoo, B. K., Emdad, L., Su, Z. Z., Villanueva, A., Chiang, D. Y., Mukhopad-
hyay, N. D., Mills, A. S., Waxman, S., Fisher, R. A., Llovet, J. M., Fisher,
P. B., and Sarkar, D. (2009) Astrocyte elevated gene-1 regulates hepatocel-
lular carcinoma development and progression. J. Clin. Invest. 119,
465–477
16. Liu, X., Zhang, N., Li, X., Moran, M. S., Yuan, C., Yan, S., Jiang, L., Ma, T.,
Haffty, B.G., andYang,Q. (2011) Identification of novel variants ofmetad-
herin in breast cancer. PLoS One 6, e17582
17. Li, X., Kong, X., Huo,Q., Guo, H., Yan, S., Yuan, C.,Moran,M. S., Shao, C.,
and Yang, Q. (2011) Metadherin enhances the invasiveness of breast can-
cer cells by inducing epithelial to mesenchymal transition. Cancer Sci.
102, 1151–1157
18. Li, J., Yang, L., Song, L., Xiong, H., Wang, L., Yan, X., Yuan, J., Wu, J., and
Li, M. (2009) Astrocyte elevated gene-1 is a proliferation promoter in
breast cancer via suppressing transcriptional factor FOXO1.Oncogene 28,
3188–3196
19. Hu, G., Wei, Y., and Kang, Y. (2009) The multifaceted role of MTDH/
AEG-1 in cancer progression. Clin. Cancer Res. 15, 5615–5620
20. Yoo, B. K., Gredler, R., Vozhilla, N., Su, Z. Z., Chen, D., Forcier, T., Shah,
K., Saxena, U., Hansen, U., Fisher, P. B., and Sarkar, D. (2009) Identifica-
tion of genes conferring resistance to 5-fluorouracil. Proc. Natl. Acad. Sci.
U.S.A. 106, 12938–12943
21. Wei, Y., Hu, G., and Kang, Y. (2009) Metadherin as a link between metas-
tasis and chemoresistance. Cell Cycle 8, 2132–2133
22. Hu, G., Chong, R. A., Yang, Q.,Wei, Y., Blanco,M. A., Li, F., Reiss, M., Au,
J. L., Haffty, B. G., and Kang, Y. (2009)MTDH activation by 8q22 genomic
gain promotes chemoresistance and metastasis of poor-prognosis breast
cancer. Cancer Cell 15, 9–20
23. Bossen, C., Tardivel, A., Willen, L., Fletcher, C. A., Perroud, M., Beer-
mann, F., Rolink, A. G., Scott, M. L., Mackay, F., and Schneider, P. (2011)
Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and
antibody responses. Eur. J. Immunol. 41, 787–797
24. Kim, S. H., Kim, K., Kwagh, J. G., Dicker, D. T., Herlyn, M., Rustgi, A. K.,
Chen, Y., and El-Deiry, W. S. (2004) Death induction by recombinant
native TRAIL and its prevention by a caspase 9 inhibitor in primary hu-
man esophageal epithelial cells. J. Biol. Chem. 279, 40044–40052
25. Schneider, P. (2000) Production of recombinantTRAIL andTRAIL recep-
tor: Fc chimeric proteins.Methods Enzymol. 322, 325–345
26. Yang, Q. F., Sakurai, T., Yoshimura, G., Shan, L., Suzuma, T., Tamaki, T.,
Umemura, T., Kokawa, Y., Nakamura, Y., Nakamura, M., Tang, W., Ut-
sunomiya, H., Mori, I., and Kakudo, K. (2000) Expression of Bcl-2 but not
Bax or p53 correlates with in vitro resistance to a series of anticancer drugs
in breast carcinoma. Breast Cancer Res. Treat. 61, 211–216
27. Chen, C., Zhou, Z., Liu, R., Li, Y., Azmi, P. B., and Seth, A. K. (2008) The
WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2
and EGFR through RING finger protein 11. Oncogene 27, 6845–6855
28. Shankar, S., Davis, R., Singh, K. P., Kurzrock, R., Ross, D.D., and Srivastava,
R. K. (2009) Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensi-
tizes TRAIL-resistant breast cancer cells orthotopically implanted in
BALB/c nude mice.Mol. Cancer Ther. 8, 1596–1605
29. Lu, M., Strohecker, A., Chen, F., Kwan, T., Bosman, J., Jordan, V. C., and
Cryns, V. L. (2008) Aspirin sensitizes cancer cells to TRAIL-induced apo-
ptosis by reducing survivin levels. Clin. Cancer Res. 14, 3168–3176
30. Zhou, Z., Liu, R., and Chen, C.(2012) The WWP1 ubiquitin E3 ligase
increases TRAIL resistance in breast cancer. Int. J. Cancer 130,
1504–1510
31. Walczak, H., and Haas, T. L. (2008) Biochemical analysis of the native
TRAIL death-inducing signaling complex. Methods Mol. Biol. 414,
221–239
32. Wang, H., Ach, R. A., and Curry, B. (2007) Direct and sensitive miRNA
profiling from low-input total RNA. RNA 13, 151–159
33. Wang, H. Y., Luo, M., Tereshchenko, I. V., Frikker, D. M., Cui, X., Li, J. Y.,
Hu, G., Chu, Y., Azaro,M. A., Lin, Y., Shen, L., Yang, Q., Kambouris,M. E.,
MTDHModulates TRAIL Resistance in Breast Cancer
9406 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 13•MARCH 29, 2013
 at B
IB
LIO
TH
EQUE DU CHUV on November 15, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Gao, R., Shih,W., and Li, H. (2005) A genotyping system capable of simul-
taneously analyzing	1000 single nucleotide polymorphisms in a haploid
genome. Genome Res. 15, 276–283
34. Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H.,
Blagosklonny,M. V., Dawson, T.M., Dawson, V. L., El-Deiry,W. S., Fulda,
S., Gottlieb, E., Green, D. R., Hengartner, M. O., Kepp, O., Knight, R. A.,
Kumar, S., Lipton, S. A., Lu, X., Madeo, F., Malorni, W., Mehlen, P., Nu-
ñez, G., Peter, M. E., Piacentini, M., Rubinsztein, D. C., Shi, Y., Simon,
H. U., Vandenabeele, P., White, E., Yuan, J., Zhivotovsky, B., Melino, G.,
and Kroemer, G. (2012) Molecular definitions of cell death subroutines:
recommendations of the Nomenclature Committee on Cell Death 2012.
Cell Death Differ. 19, 107–120
35. Wu, G. S. (2009) TRAIL as a target in anti-cancer therapy. Cancer Lett.
285, 1–5
36. Maksimovic-Ivanic, D., Stosic-Grujicic, S., Nicoletti, F., and Mijatovic, S.
(2012) Resistance to TRAIL and how to surmount it. Immunol. Res. 52,
157–168
37. Yoon,M. J., Park, S. S., Kang, Y. J., Kim, I. Y., Lee, J. A., Lee, J. S., Kim, E. G.,
Lee, C. W., and Choi, K. S. (2012) Aurora B confers cancer cell resistance
to TRAIL-induced apoptosis via phosphorylation of survivin.Carcinogen-
esis 33, 492–500
38. Keane, M. M., Ettenberg, S. A., Nau, M. M., Russell, E. K., and Lipkowitz,
S. (1999) Chemotherapy augments TRAIL-induced apoptosis in breast
cell lines. Cancer Res. 59, 734–741
39. Lee, S. G., Su, Z. Z., Emdad, L., Sarkar, D., Franke, T. F., and Fisher, P. B.
(2008) Astrocyte elevated gene-1 activates cell survival pathways through
PI3K-Akt signaling. Oncogene 27, 1114–1121
40. Xu, J., Zhou, J.-Y., Wei, W.-Z., andWu, G. S. (2010) Activation of the Akt
survival pathway contributes to TRAIL resistance in cancer cells. PLoS
One 5, e10226
41. Fulda, S., Meyer, E., and Debatin, K.-M. (2002) Inhibition of TRAIL-in-
duced apoptosis by Bcl-2 overexpression. Oncogene 21, 2283–2294
42. Bartel, D. P. (2009) MicroRNAs: target recognition and regulatory func-
tions. Cell 136, 215–233
43. Mehta, K., Devarajan, E., Chen, J., Multani, A., and Pathak, S. (2002) Mul-
tidrug-resistant MCF-7 cells: an identity crisis? J. Natl. Cancer Inst. 94,
1652–1654; author reply 1654
44. Seol, D. W., Li, J., Seol, M. H., Park, S. Y., Talanian, R. V., and Billiar, T. R.
(2001) Signaling events triggered by tumor necrosis factor-related apop-
tosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced
apoptosis. Cancer Res. 61, 1138–1143
MTDHModulates TRAIL Resistance in Breast Cancer
MARCH 29, 2013•VOLUME 288•NUMBER 13 JOURNAL OF BIOLOGICAL CHEMISTRY 9407
 at B
IB
LIO
TH
EQUE DU CHUV on November 15, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
